Increased Concentrations of Apo A-I and Apo A-II Fragments in the Serum of Patients With Hepatocellular Carcinoma by Magnetic Beads–Assisted MALDI-TOF Mass Spectrometry. Issue 1 (1st January 2014)

• Record Type: Journal Article
• Authors: Liu, Yang; Sogawa, Kazuyuki; Sunaga, Masahiko; Umemura, Hiroshi; Satoh, Mamoru; Kazami, Takahiro; Yoshikawa, Masaharu; Tomonaga, Takeshi; Yokosuka, Osamu; Nomura, Fumio
• Is Part Of: American journal of clinical pathology. Volume 141:Issue 1(2014)
• Page Start: 52
• Page End: 61
• Publication Date: 2014-01-01
• Subjects: Hepatocellular carcinoma -- MALDI-TOF MS -- Apolipoprotein A-I -- Apolipoprotein A-II; Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; 616.07
• DOI: 10.1309/AJCPBLFBNAP6N2UN
• Languages: English
• ISSNs: 0002-9173

Abstract

Abstract: Objectives: Recent advances in sophisticated technologies in proteomics should provide promising ways to discover novel markers for hepatocellular carcinoma (HCC) in the early diagnosis. Methods: Serum peptide and protein profiling was conducted by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Profiling was carried out in a training set of 16 patients with HCC and a testing set of 15 patients with cirrhosis without HCC. All the patients were hepatitis C virus positive. Candidate peaks were processed to partial purification, followed by protein identification by amino acid sequence analysis. Immunoprecipitation was conducted to confirm the protein identity. Results: Partial purification and protein identification revealed that one peak that was up-regulated in HCC sera both in the training and the testing sets was a fragment of apolipoprotein A-I (apo A-I). Immunoprecipitation confirmed this result. Conclusions: MALDI-TOF MS analysis revealed that apo A-I is a potential novel serum marker of HCC. Combination of these pretreatments and the current magnet bead–assisted MALDI-TOF MS will further enhance the efficiency of biomarker discovery for HCC.